TOKYO, Mar 25 (Pulse News Wire) – D.Western Therapeutics Institute, Inc. (4576.T) updated its development plan for glaucoma treatment agent H-1337, prioritizing Japanese clinical trials due to recent capital tie-ups.
The company now plans to commence Phase 3 studies in both Japan and the United States, targeting estimated patient populations of four million in Japan and in the U.S. Previously, the focus was solely on U.S. markets, but the revised strategy includes additional funding considerations for Phase 3 investment in Japan.
The update also reflects changes in growth scenarios, emphasizing efficiency and value creation through streamlined development processes. In addition, the company's pipeline expansion remains a key priority, with ongoing investments aimed at advancing multiple projects towards clinical development stages. Financial milestones such as royalty revenues from existing products DW-5LBT and GraAlpha continue to support future growth strategies.
🔴 Confidence: Review recommended AI-translated content.